Mikhail Kosiborod MD

Echocardiography, Preventive Cardiology

Professor of Medicine (Cardiology), Saint Luke's Mid America Heart Institute, University of Missouri, Kansas City School of Medicine

Join to view full profile

4330 Wornall RdSte 2000Kansas City, MO 64111
Phone+1 816-931-1883
Fax+1 816-756-3645

Dr. Kosiborod is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kosiborod's full profile Already have an account?

Education & Training

Yale-New Haven Medical CenterFellowship, Cardiovascular Disease, 2001 - 2004
Yale-New Haven Medical CenterResidency, Internal Medicine, 1997 - 2001
Icahn School of Medicine at Mount SinaiClass of 1997

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

KS State Medical License 2005 - 2027
MO State Medical License 2005 - 2027
CT State Medical License 2000 - 2006
American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012, 2014-2017
CMS Meaningful Use Stage 2 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012, 2014-2017

Clinical Trials

Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)
COMPLETED
MANAGE Automated Glucose Monitoring
UNKNOWN
NA
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure Start of enrollment: 2016 Mar 03
COMPLETED
PHASE4

Publications & Presentations

PubMed

1 citations
Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure: A Prespecified Analysis From EMPULSE.
Christiane E Angermann, Teresa Gerhardt, Jonathan P Blatchford, Jan Biegus, Sean P Collins
JACC. Heart Failure. 2026-08-01
Optimizing Care in Cardiovascular-Kidney-Metabolic Syndrome: Registry Data From the Cardiometabolic Center Alliance.
Ian J Neeland, Melissa L Magwire, Audrey Kwun, Daniel S Aistrope, Emily Ann Kapunan Andaya
Circulation. Population Health and Outcomes. 2026-07-01
1 citations
Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.
Elke Platz, Lee M Kaplan, Carel W le Roux, Sean Wharton, Svenja Burger
JACC. Heart Failure. 2026-05-01

Journal Articles

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients with Heart Failure with Reduced Ejection Fraction
Mikhail N Kosiborod, Marc S Sabatine, JAMA Cardiology
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients with Heart Failure with and Without Diabetes
Akshay S Desai, Mikhail N Kosiborod, Marc S Sabatine, JAMA
Real‐World Opportunity of Empagliflozin to Improve Blood Pressure Control in African Americans with Type 2 Diabetes: An NCDR® “Research‐to‐Practice” Project from the D...
Suzanne V Arnold, Mikhail Kosiborod, Diabetes, Obesity and Metabolism

Lectures

Drug Choices in Diabetes and Heart Failure Advice for the Practicing Cardiologist
2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
Changing Paradigm in Cardiovascular Risk Reduction in Diabetes
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Initiation of Sodium Glucose Cotransporter-2 Inhibitors Versus Other Glucose Lowering Drugs and Risk of Hospitalization For Heart Failure and Death in Patients With Ty...
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019

Authored Content

ACC CardiaCast: Emerging Data in SGLT2 InhibitorsJune 2018
: An Analysis of CVD-REALJune 2018

Press Mentions

Integrated Resources Set to Enhance Cardiovascular, Kidney, and Metabolic HealthcareOctober 1st, 2025
Combined Resources Will Improve Cardiovascular-Kidney-Metabolic CareOctober 1st, 2025
REALIZE-K: MRA Treatment Optimization in HFrEF plus HyperkaliemiaNovember 26th, 2024